NYXH · Company research
Nyxoah SA (NYXH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 | Nyxoah reported Q3 2026 global net revenue of €9.2 million with 29% sequential U.S. growth, but lowered full-year 2026 revenue guidance to €33-35 million from €36-40 million. The company submitted a PMA supplement to expand its Genio hypoglossal nerve stimulation system to Complete Concentric Collapse patients, with the ACCCESS study meeting efficacy endpoints at 77.2% AHI responder rate. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | neutral | 0 | 1 |
| Nyxoah Annonce ses Résultats Préliminaires pour le Troisième Trimestre 2026 et Ajuste ses Prévisions de Chiffre d’Affaires pour 2026 | Nyxoah reported Q3 2026 net revenue of €9.2 million with 29% sequential growth in US sales. The company submitted a PMA supplement to the FDA to expand Genio's indication to complete concentric collapse patients, with the ACCCESS study meeting primary efficacy endpoints (77.2% responder rate). However, full-year 2026 revenue guidance was lowered to €33-35 million from €36-40 million. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | neutral | 0 | 1 |
| Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains? | Schrodinger shares surged 7.6% to close at $32.6, driven by investor optimism following the announcement of Tectora, a new biotech company co-founded by Schrodinger, NEA, and RA Capital Management focused on immunology and inflammation therapies. The company secured $55 million in Series A funding. Despite expected quarterly losses of $0.66 per share and a 15.3% revenue decline, consensus EPS estimates have been revised 72.2% higher over the past 30 days, suggesting potential for continued strength. SDGR carries a Zacks Rank #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains? | Schrodinger shares surged 7.6% to close at $32.6, driven by investor optimism following the announcement of Tectora, a new biotech company co-founded by Schrodinger, NEA, and RA Capital Management focused on immunology and inflammation therapies. The company secured $55 million in Series A funding. Despite expected quarterly losses of $0.66 per share and a 15.3% revenue decline, consensus EPS estimates have been revised 72.2% higher over the past 30 days, suggesting potential for continued strength. SDGR carries a Zacks Rank #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.5 | 1 |
| Nyxoah (NASDAQ: NYXH) Stock Price, News & Analysis - Kalkine | Nyxoah (NASDAQ: NYXH) Stock Price, News & Analysis Kalkine | View source ↗ | Kalkine | Oct 2, 2026 | neutral | 0 | 0.6 |
| Nyxoah Taps Former Teleflex Chief Liam Kelly to Lead U.S.-Focused Growth Drive - The Globe and Mail | Nyxoah Taps Former Teleflex Chief Liam Kelly to Lead U.S.-Focused Growth Drive The Globe and Mail | View source ↗ | The Globe and Mail | Sep 29, 2026 | neutral | 0 | 0.6 |
| A former medical-device CEO will lead Nyxoah while its U.S. launch is still in early stages. - Stock Titan | A former medical-device CEO will lead Nyxoah while its U.S. launch is still in early stages. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| A medical technology company expects €36M–€40M in 2026 revenue. Nyxoah’s finance chief is set to leave. - Stock Titan | A medical technology company expects €36M–€40M in 2026 revenue. Nyxoah’s finance chief is set to leave. Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| NYXH Stock Jumps As ACCCESS Trial De‑Risks Sleep Apnea Bet - StocksToTrade | NYXH Stock Jumps As ACCCESS Trial De‑Risks Sleep Apnea Bet StocksToTrade | View source ↗ | StocksToTrade | Sep 3, 2026 | neutral | 0 | 0.6 |
| NYXH Stock Pops As ACCCESS Trial Data Fuels Breakout Hopes - Timothy Sykes | NYXH Stock Pops As ACCCESS Trial Data Fuels Breakout Hopes Timothy Sykes | View source ↗ | Timothy Sykes | Sep 3, 2026 | neutral | 0 | 0.6 |
| Nyxoah (ENXTBR:NYXH) Stock Forecast & Analyst Predictions - Simply Wall Street | Nyxoah (ENXTBR:NYXH) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 3, 2026 | neutral | 0 | 0.6 |
| Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ) - Seeking Alpha | Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 3, 2026 | neutral | 0 | 0.6 |
| Avoiding Lag: Real-Time Signals in (NYXH) Movement - Stock Traders Daily | Avoiding Lag: Real-Time Signals in (NYXH) Movement Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 4, 2026 | neutral | 0 | 0.6 |
| NYXH Forecast — Price Target — Prediction for 2027 - TradingView | NYXH Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Analyst Cuts And Capital Concerns - Yahoo Finance | Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Analyst Cuts And Capital Concerns Yahoo Finance | View source ↗ | Yahoo Finance | Jun 23, 2026 | neutral | 0 | 0.6 |
| Why Is NYXH Stock Falling Today? - Yahoo Finance | Why Is NYXH Stock Falling Today? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 5, 2026 | neutral | 0 | 0.6 |
| NYXH - Finviz | NYXH Finviz | View source ↗ | Finviz | May 31, 2026 | neutral | 0 | 0.6 |
| Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance | Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Mar 19, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.